Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

By Priya Kalia, SciTribe and Miranda Weston-Smith, BioBeat.

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...